Drug Trial Radar · NCT04408820
Post-marketing Surveillance of EVRENZO® Tablets (Roxadustat) in Patients With Renal Anemia
Last checked: Nov 19, 2026Latest source record: Jul 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,104
Actual
Start
Jun 1, 2020
Primary completion
Jun 23, 2025
Study completion Jun 23, 2025
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- May 29, 2020
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and efficacy, including the incidence of thromboembolism, in renal anemia patients treated with roxadustat (EVRENZO® Tablets) in actual clinical settings.
Conditions
- Renal Anemia
Interventions
RoxadustatDrug
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with Adverse Drug Reactions (ADR)Time frame: Up to Week 104
- Proportion of participants with serious ADRTime frame: Up to Week 104
- Proportion of participants with thromboembolismTime frame: Up to Week 104
- Proportion of participants with hypertensionTime frame: Up to Week 104
- Proportion of participants with hepatic function disorderTime frame: Up to Week 104
- Proportion of participants with malignant tumorsTime frame: Up to Week 104
- Proportion of participants with retinal hemorrhageTime frame: Up to Week 104
- Proportion of Participants With SeizuresTime frame: Up to week 104
- Proportion of Participants With Serious InfectionTime frame: Up to week 104
- Proportion of Participants With Central HypothyroidsmTime frame: Up to Week 104
- Proportion of participants with myopathy eventsTime frame: Up to Week 104
- Proportion of Participants With Renal Function DisorderTime frame: Up to week 104
- Proportion of participants with ADR within 4 weeks after switching to roxadustatTime frame: Up to Week 4
- Proportion of participants with ADR with high doses of roxadustatTime frame: Up to Week 104
- Change from baseline in Hemoglobin (Hb) levelsTime frame: Up to Week 104
- Mean value of Hb levels over timeTime frame: Up to Week 104
- Achievement rate for target Hb levelTime frame: Up to Week 104
- Mean Hb levels at 4 weeks after switching to roxadustatTime frame: At Week 4
Locations
47 sites in 1 country. Site status is shown where the registry gives one.
Site JP00023
Aichi, Japan
Site JP00005
Akita, Japan
Site JP00002
Aomori, Japan
Site JP00012
Chiba, Japan
Site JP00038
Ehime, Japan
Site JP00018
Fukui, Japan
Site JP00040
Fukuoka, Japan
Site JP00007
Fukushima, Japan
Site JP00021
Gifu, Japan
Site JP00010
Gunma, Japan
Site JP00034
Hiroshima, Japan
Site JP00001
Hokkaido, Japan
Site JP00028
Hyōgo, Japan
Site JP00008
Ibaraki, Japan
Site JP00017
Ishikawa, Japan
Site JP00037
Kagawa, Japan
Site JP00046
Kagoshima, Japan
Site JP00014
Kanagawa, Japan
Site JP00039
Kochi, Japan
Site JP00043
Kumamoto, Japan
Site JP00026
Kyoto, Japan
Site JP00024
Mie, Japan
Site JP00004
Miyagi, Japan
Site JP00045
Miyazaki, Japan
Site JP00020
Nagano, Japan
Site JP00042
Nagasaki, Japan
Site JP00029
Nara, Japan
Site JP00015
Niigata, Japan
Site JP00003
Numakunai, Japan
Site JP00044
Ōita, Japan
Site JP00033
Okayama, Japan
Site JP00047
Okinawa, Japan
Site JP00027
Osaka, Japan
Site JP00041
Saga, Japan
Site JP00011
Saitama, Japan
Site JP00025
Shiga, Japan
Site JP00032
Shimane, Japan
Site JP00022
Shizuoka, Japan
Site JP00009
Tochigi, Japan
Site JP00036
Tokushima, Japan
Showing 40 of 47 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.